Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Ad
This is a Phase 2, single-arm study to evaluate the safety and efficacy of relacorilant in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic adenocarcinoma (PDAC).
| Condition(s) | Adenocarcinoma, Carcinoma, Pancreatic Ductal |
|---|---|
| Status | Recruiting |
| Phase | Phase 2 |
| Study type | Interventional |
| Summary | This is a Phase 2, single-arm study to evaluate the safety and efficacy of relacorilant in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic adenocarcinoma (PDAC). |
| Who can participate | Inclusion Criteria: * Signed and dated informed consent form prior to screening procedures * Histologic diagnosis or cytologic diagnosis of pancreatic adenocarcinoma (PDAC) * Initial diagnosis of metastatic disease occurred ≤6 weeks prior to enrollment in the study * Life expectancy of ≥3 months * Radiographic confirmation of metastatic disease with at least 1 distant tumor metastasis measurable on radiology imaging per RECIST version 1.1 criteria * Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 * Able to provide informed consent and comply with protocol requirements * Able to swallow and retain oral medication and does not have uncontrolled emesis * Has adequate gastrointestinal absorption * Received no prior systemic anticancer therapy to treat metastatic disease * I |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | Corcept Therapeutics |
| Locations | Scottsdale, Arizona, United States; Los Angeles, California, United States; Atlanta, Georgia, United States; Grand Rapids, Michigan, United States; East Brunswick, New Jersey, United States; Albany, New York, United States (+4 more sites) |
| Start date | 2026-01-27 |
| NCT ID | NCT07259317 |
| Official listing | https://clinicaltrials.gov/study/NCT07259317 |